These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17202834)

  • 21. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.
    Drexler I; Antunes E; Schmitz M; Wölfel T; Huber C; Erfle V; Rieber P; Theobald M; Sutter G
    Cancer Res; 1999 Oct; 59(19):4955-63. PubMed ID: 10519409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigen-specific transfer of functional programmed death ligand 1 from human APCs onto CD8+ T cells via trogocytosis.
    Gary R; Voelkl S; Palmisano R; Ullrich E; Bosch JJ; Mackensen A
    J Immunol; 2012 Jan; 188(2):744-52. PubMed ID: 22174448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct antigen presentation by DC shapes the functional CD8(+) T-cell repertoire against the nuclear self-antigen La-SSB.
    Keech CL; Pang KC; McCluskey J; Chen W
    Eur J Immunol; 2010 Feb; 40(2):330-8. PubMed ID: 19950171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro.
    Han H; Peng JR; Chen PC; Gong L; Qiao SS; Wang WZ; Cui ZQ; Yu X; Wei YH; Leng XS
    Biochem Biophys Res Commun; 2011 Aug; 411(3):530-5. PubMed ID: 21756876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells.
    Bellone M; Iezzi G; Manfredi AA; Protti MP; Dellabona P; Casorati G; Rugarli C
    Eur J Immunol; 1994 Nov; 24(11):2691-8. PubMed ID: 7525300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamber-associated immune deviation.
    Kezuka T; Streilein JW
    Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1803-11. PubMed ID: 10845601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of tissue-specific H-2Kd transgenic mice for the study of K(d)-restricted malaria epitope-specific CD8+ T-cell responses in vivo.
    Huang J; Li X; Kohno K; Hatano M; Tokuhisa T; Murray PJ; Brocker T; Tsuji M
    J Immunol Methods; 2013 Jan; 387(1-2):254-61. PubMed ID: 23142461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An antigen-targeted approach to adoptive transfer therapy of cancer.
    Valmori D; Pittet MJ; Rimoldi D; Liénard D; Dunbar R; Cerundolo V; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 1999 May; 59(9):2167-73. PubMed ID: 10232604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction.
    Lees JR; Charbonneau B; Hayball JD; Diener K; Brown M; Matusik R; Cohen MB; Ratliff TL
    Prostate; 2006 May; 66(6):578-90. PubMed ID: 16388504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
    Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
    Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
    Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
    Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.
    Hu X; Chakraborty NG; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
    Cancer Res; 1996 Jun; 56(11):2479-83. PubMed ID: 8653680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells.
    Melenhorst JJ; Solomon SR; Shenoy A; Hensel NF; McCoy JP; Keyvanfar K; Barrett AJ
    J Immunother; 2006; 29(4):436-43; discussion 365-6. PubMed ID: 16799339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
    Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
    Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
    Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
    Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses.
    Song S; Jin X; Zhang L; Zhao C; Ding Y; Ang Q; Khaidav O; Shen C
    Int J Nanomedicine; 2019; 14():2465-2483. PubMed ID: 31040669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allo-restricted CTLs generated by coculturing of PBLs and autologous monocytes loaded with allogeneic peptide/HLA/IgG1-Fc fusion protein.
    Weng X; Lu S; Zhong M; Liang Z; Shen G; Chen J; Wu X
    J Leukoc Biol; 2009 Mar; 85(3):574-81. PubMed ID: 19112092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
    Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
    Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
    Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
    J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.